Cleavage of huntingtin (htt) has been characterized in vitro, and accumulation of caspase cleavage fragments represents an early pathological change in brains of Huntington's disease (HD) patients. However, the relationship between htt proteolysis and the pathogenesis of HD is unknown. To determine whether caspase cleavage of htt is a key event in the neuronal dysfunction and selective neurodegeneration in HD, we generated YAC mice expressing caspase-3-and caspase-6-resistant mutant htt. Mice expressing mutant htt, resistant to cleavage by caspase-6 but not caspase-3, maintain normal neuronal function and do not develop striatal neurodegeneration. Furthermore, caspase-6-resistant mutant htt mice are protected against neurotoxicity induced by multiple stressors including NMDA, quinolinic acid (QA), and staurosporine. These results are consistent with proteolysis of htt at the caspase-6 cleavage site being an important event in mediating neuronal dysfunction and neurodegeneration and highlight the significant role of htt proteolysis and excitotoxicity in HD.
INTRODUCTION
Huntington's disease (HD), a neurodegenerative disorder characterized by progressive deterioration of cognitive and motor functions, is caused by an expansion of a trinucleotide (CAG) repeat encoding glutamine in the N terminus of huntingtin (htt). Polyglutamine expansion results in selective loss of GABAergic medium spiny striatal neurons as well as glutamatergic cortical neurons that project to the striatum (Albin et al., 1990 (Albin et al., , 1992 . A neuropathological hallmark in human HD and mouse models is the intracellular accumulation of N-terminal htt fragments Kim et al., 2001) , suggesting that aberrant htt proteolysis and/or dysfunctional clearance of htt fragments may underlie the neuropathology in HD.
Several proteases, including caspases, calpains, and aspartyl endopeptidases, cleave htt within the N-terminal region Lunkes et al., 2002; Gafni et al., 2004) , and in vitro studies have demonstrated that expanded N-terminal htt fragments have enhanced cytotoxicity . Furthermore, although some HD mouse models expressing truncated mutant htt (mhtt) demonstrate behavioral deficits and neuronal inclusions (Davies et al., 1997; Schilling et al., 1999) , in vivo expression of an expanded N-terminal htt fragment containing exons 1 and 2 (the shortstop model) does not result in a behavioral or neurodegenerative phenotype , demonstrating that N-terminal htt fragments do not per se invariably result in pathology. In addition, while several studies have shown that translocation of htt to the nucleus is associated with increased toxicity in vitro and neuropathology in vivo (Wheeler et al., 2000; Wellington et al., 2002) , the shortstop mouse exhibits widespread diffuse nuclear htt but no neurotoxicity, suggesting either that N-terminal fragments containing the mutation alone are insufficient to cause the disease or that a specific nuclear htt fragment is critical for the neuronal degeneration in HD. In the YAC128 model, which expresses full-length mhtt, nuclear localization of htt fragments occurs earliest and to the greatest extent in the striatum, the region most affected in HD (Van Raamsdonk et al., 2005a) .
htt is cleaved by caspase-3 and -6 in vitro, and caspase-3-cleaved htt fragments are detectable in HD brain prior to the clinical onset . In addition, site-directed mutagenesis of all five caspase cleavage sites in mhtt blocks cytotoxicity in vitro (Wellington et al., 2000) . These observations raise the questions of whether the caspase-specific htt fragments are important in the pathogenesis of HD and whether inhibiting caspase cleavage of mhtt may be protective in vivo.
We have previously developed a YAC model for HD that displays age-and CAG-dependent phenotypes that recapitulate many features of the human disease. Specifically, enhanced susceptibility to excitotoxic stress, cleavage and nuclear localization of htt, and cognitive dysfunction are followed by motor deficits and selective striatal degeneration (Slow et al., 2003; Van Raamsdonk et al., 2005a , 2005b Graham et al., 2005) , recapitulating many aspects of human HD.
To determine whether caspase cleavage of mhtt represents a primary event in the pathogenesis of HD in vivo, we generated YAC mice expressing expanded htt containing selective mutations of the caspase-3 and caspase-6 cleavage sites.
Here we report that cleavage at the 586 amino acid (aa) caspase-6 site in mhtt is required for the development of the characteristic behavioral and neuropathological features of HD. Selective elimination of the caspase-6, but not caspase-3, cleavage site in mhtt is sufficient to provide protection from neuronal dysfunction and neurodegeneration in vivo. These data suggest that specific mhtt fragments are required to initiate a toxic cycle that leads to neuronal dysfunction and the neuropathological abnormalities in HD. Our results are consistent with in vivo proteolytic cleavage of mhtt at the caspase-6 cleavage site being a crucial and rate-limiting event in the pathogenesis of HD and suggest that preventing caspase-6 cleavage of htt may be of therapeutic interest. (Wellington et al., 2000) . Specific mutations of the P1 aspartate at positions 513 and 552 would be expected to generate C3R htt, and a mutation at residue 586 would be expected to generate C6R htt. To ensure that the silent caspase-3 sites would be unable to be cryptically activated in vivo, we also mutagenized their P1 aspartate residues.
RESULTS

Generation of Caspase-Resistant Lines
The mutagenized exons were introduced by homologous recombination in yeast into YAC353G6 (see the Supplemental Experimental Procedures and Figure S1 in the Supplemental Data available with this article online) and verified by Southern blot and PCR (data not shown). Verified caspase-resistant (CR) YACs were purified and microinjected into FVB/N pronuclei (Hodgson et al., 1999) . Founders were confirmed by a five-point PCR screen (Figure S2) and by sequencing (data not shown).
Using this strategy, we generated two independent mouse lines expressing human mhtt resistant to both caspase-3 and -6 known as caspase quint resistant (CQR) lines 24 (CQR24) and 26 (CQR26). We also developed two independent lines selectively resistant to caspase-3 (C3R8 and C3R9) and two resistant to caspase-6 (C6R7 and C6R13).
Characterization of CAG Size and Transgene Expression Levels
The phenotype of HD in YAC128 mice is influenced by levels of expression of mhtt ; therefore, it is essential to control not only for CAG size but also for levels of transgene expression.
PCR-mediated CAG sizing was used to ensure equivalent CAG sizes among caspase-cleavable and CR lines ( Figure 1A ). Lines HD53, HD54, CQR24, C3R8, and C3R9 all contain 120 CAG repeats. Lines C6R7 and C6R13 each have 133 CAGs, and CQR26 contains two CAG sizes of 120 and 83. Thus, all of the CR lines have CAG sizes at least as large as the control YAC lines.
Quantitative mRNA and Western blotting was then used to match transgene expression in each CR murine brain tissue to the most appropriate YAC128 line (n = 3, age matched). htt expression levels in CQR24 and CQR26 (upper allele) were found to be equivalent to HD54 (Figures 1B and 1C) . The CQR26 mice display two distinct protein sizes on Western blots ( Figure 1C ), which was accounted for by a spontaneous contraction of the glutamine tract in one copy of the YAC in CQR26 animals. htt expression analysis in C3R8 and C3R9 demonstrates that both of these lines also express human mhtt at levels equivalent to HD54 (Figures 1B and 1C) , whereas mhtt levels in C6R7 and C6R13 mice are similar to the previously described HD53 mice and higher than HD55 ( Figures 1B  and 1C) . The different forms of mhtt are expressed similarly in different regions of CR and caspase-cleavable (YAC128) murine brain ( Figure S3 ).
Caspase-Resistant htt Expressed in CR Mice Is Resistant to Caspase Proteolysis
Western blotting shows that caspase-3 and -6 do not cleave htt in CQR24 or CQR26 brain lysates (Figure 2A) , verifying that the mutations introduced into CQR mhtt block cleavage of mhtt by caspases-3 and -6. In contrast, HD54 brain lysates give rise to the expected htt caspase fragments (70 kDa for endogenous and 98 kDa for mhtt) (Figure 2A ).
Western blotting demonstrates that caspase-3 cleaves only endogenous htt in brain lysates prepared from C3R8 and C3R9 mice ( Figure 2B ). In contrast, caspase-3 treatment of lysates prepared from HD54 brain generated the expected 70 kDa and 98 kDa htt fragments representing the endogenous and mhtt protein. Incubation of C3R lysates with caspase-6 results in the expected fragments from endogenous and mhtt, demonstrating that C3R mhtt is only resistant to cleavage by caspase-3 ( Figure 2D ).
Conversely, treatment of brain lysates from HD53 with caspase-6 generated the expected caspase-6 fragments from transgenic (115 kDa) and endogenous htt (90 kDa) ( Figure 2C ). As expected, only endogenous htt is cleaved by caspase-6 in brain lysates from C6R7 and C6R13 mice ( Figure 2C ). This caspase-6 mhtt fragment is detected in vivo in HD53, HD54, and C3R brain lysates, while it is absent in C6R brain lysates (C6R7 and C6R13, Figure 2E ). Assessment of the toxicity of the 586 aa N-terminal mhtt fragment in vitro demonstrates that it is more toxic than the caspase-3 513 aa or 552 aa mhtt fragments in transfected N2A cells exposed to staurosporine (n = 3, ANOVA p = 0.0015; Figure S4 ). Incubation of C6R brain lysates with caspase-3 results in caspase-3 endogenous and mhtt fragments, demonstrating that C6R mhtt is selectively resistant to cleavage by caspase-6 ( Figure 2F ). This is further substantiated in vivo using the caspase-3 neo-epitope antibody (htt552) . htt552 immunostaining of brain slices from wild-type (wt), HD53, and C6R mice demonstrates the presence of htt cleaved at aa 552 predominantly in the cytoplasm and processes of a subset of striatal neurons in all mice irrespective of genotype ( Figure 2G ). YAC 18, 46, 72, and 128 (HD53 and 54) lines (described previously, Hodgson et al., 1996; Graham et al., 2005) and CQR24, CQR26, C3R8, C3R9, C6R7, and C6R13. Wild-type is included as a negative control. Lines HD53, HD54, CQR24, C3R8, and C3R9 all display a 120 CAG repeat size. Lines C6R7 and C6R13 have 133 CAG repeats, and CQR26 contains two CAG sizes of 120 and 83. (B) Real-time quantitative RT-PCR showing mRNA transgene levels in CR murine brain compared against YAC128 (n = 3). mhtt levels in CQR24 are equivalent to HD54. CQR26 demonstrates approximate doubling of mhtt levels due to contribution from two alleles (left panel). Transgene levels in C3R8 and C3R9 are equivalent to HD54 (middle panel). mhtt expression levels in C6R7 and C6R13 are similar to HD53 and higher than HD55 (right panel). (C) High-resolution Western blot of CR and YAC128 brain tissue probed with BKP1 htt antibody (upper panels). mhtt level of upper allele in CQR26 (120 CAG) is similar to HD54. Quantification of mhtt protein levels in CR and YAC128 murine brain (lower panels) correlates with mRNA levels. Transgene protein levels have been normalized to endogenous htt. Mean measurements and densitometric ratios of mutant htt/endogenous htt are ±SD (n = 3).
Caspase-Resistant Mutant htt Retains Developmental Functions In Vivo
Transgenic htt expressed from a YAC rescues the embryonic lethality of htt-deficient animals (Hodgson et al., 1996) . We observe rescue of embryonic lethality of httknockout mice with a similar efficiency in CR YAC lines and YAC mice expressing caspase-cleavable htt, demonstrating that mutagenesis of the caspase sites in mhtt (E) Western blot probed with 1C2 antibody demonstrates that a mutant htt fragment (arrow), running at the same size as the mutant htt fragment generated by caspase-6 cleavage (lane 1), is observed in HD53 cortex and striatum lysates (lane 2); this band is not present in either of the C6R cortex or striatum lysates (C6R7, lane 3 and C6R13, lane 4). The caspase-6 mhtt fragment is also observed in HD54 and C3R cortex lysates (lanes 6 and 7). Actin is included as a loading control. (F) Caspase-3 cleaves mhtt in C6R mice, resulting in a 98 kDa fragment; the 70 kDa band represents cleaved endogenous htt. (G) htt552 immunostaining of striatum from wt, HD53, and C6R mice shows the presence of htt cleaved at aa 552 predominantly in the cytoplasm and processes of a subset of striatal neurons. C3R mice on an htt knockout background (C3R À/À ) are included as a negative control. Scale bar = 10 mm. All Western blots were probed with BKP1 except where noted.
does not impair htt function in vivo during development (Table S1 ). In YAC mice expressing low levels of mhtt (HD54 and C3R9), only partial rescue is observed, consistent with observations that developmental viability requires a threshold level of htt expression (Auerbach et al., 2001 ).
Inhibition of Caspase Cleavage of Huntingtin Prevents Neurodegeneration In Vivo
Significant brain atrophy and loss of striatal volume have previously been reported in HD53 mice by 9 months (Slow et al., 2003) , in HD55 by 12 months, and in the lower-expressing HD54 line by 18 months . First, we measured brain weights and striatal volumes in CQR and HD54 mice at 18 months (n = 8). No reduction in brain weight is observed for either the CQR24 or the CQR26 line compared to wt mice (CQR (pooled) = 0.39 ± 0.01 g, wt = 0.40 ± 0.02 g, p = 0.14; Figure 3A ). As expected, HD54 brain weights are significantly lower than wt controls at 18 months (HD54 = 0.37 ± 0.01 g, p = 0.02). Similarly, striatal volume is reduced by 9% in HD54 mice relative to wt controls (HD54 = 11.9 ± 0.65 mm 3 , wt = 13.2 ± 0.96 mm 3 , p = 0.03; Figure 3A ). By contrast, CQR24 and CQR26 mice do not exhibit any significant reduction in striatal volume at 18 months compared to wt mice (CQR (pooled) = 12.6 ± 0.74 mm 3 , p = 0.22). These observations suggest that caspase cleavage of mhtt is required for striatal volume loss.
To distinguish whether caspase-3 or -6 cleavage of mhtt, or both, is critical for mediating striatal atrophy, we next evaluated brain weights and striatal volumes in the C3R lines relative to the appropriate control line HD54 and wt mice (n = 8). At 18 months, brain weight and striatal volumes in the C3R lines (pooled) are indistinguishable from HD54 (brain weight C3R = 0.37 ± 0.02 g, HD54 = 0.37 ± 0.01 g, p = 0.75; striatal volume C3R = 11.8 ± 0.90 mm 3 , HD54 = 11.9 ± 0.65 mm 3 , p = 0.84; Figure 3B ) and significantly less than wt controls (brain weight wt = 0.40 ± 0.02 g, p = 0.002; striatal volume wt = 13.2 ± 0.96 mm 3 , p = 0.003). These findings demonstrate that preventing caspase-3 cleavage of mhtt provides no protection from striatal atrophy in vivo. Notably, mice expressing C3R mhtt still generate caspase-6 fragments of mhtt ( Figures 2D and 2E) .
We next evaluated whether caspase-6 cleavage of mhtt influences brain weight and striatal volume in vivo. As expected , HD53 brain weight and striatal volume are reduced compared to wt controls at 18 months (n = 8, brain weight HD53 = 0.35 ± 0.01 g, wt = 0.38 ± 0.02 g, p = 0.04; striatal volume HD53 = 10.9 ± 0.40 mm 3 , wt = 12.9 ± 0.42 mm 3 , p < 0.0001; Figure 3C ). By contrast, brain weight and striatal volume from C6R7 and C6R13 lines (pooled) are indistinguishable from wt controls (n = 8, brain weight C6R = 0.38 ± 0.03 g, C6R versus wt: p = 0.61; striatal volume C6R = 12.3 ± 0.83 mm 3 , C6R versus wt: p = 0.10), and striatal volume is significantly increased relative to HD53 (p < 0.01, ANOVA p = 0.0004; Figure 3C ). These data demonstrate that selective mutation of the caspase-6 site in mhtt is sufficient to protect mice from the neurotoxic effects of polyglutamine expansion and striatal volume loss in vivo. We then assessed striatal volume and neuronal counts in C6R mice compared to HD53 animals at 12 months (n = 7). As expected (Slow et al., 2003) , HD53 mice demonstrate significant striatal volume and neuronal loss at 12 months (striatal volume HD53 = 11.0 ± 0.74 mm 3 , wt = 12.6 ± 0.84 mm Figure 3D ). Mice expressing C6R mhtt still generate a caspase-3 fragment of mhtt (Figures 2F and 2G) , which clearly has no neurotoxicity in vivo. These observations suggest that selective cleavage of mhtt by caspase-6, but not caspase-3, is a critical step in development of striatal atrophy.
Inhibiting Caspase Cleavage of Mutant Huntingtin
Protects against Motor Dysfunction HD53 and HD55 mice develop cognitive and motor abnormalities that recapitulate many clinical features of HD (Van Raamsdonk et al., 2005b; Graham et al., 2005) . To investigate motor dysfunction, wt, HD53, and C6R mice (sex and weight matched, n = 9) were assessed using an accelerating rotarod. HD53 mice show a significant deficit on the rotarod at 2 months (p < 0.01; Figure 4A ). By contrast, C6R mice perform as well as wt animals up to and including 10 months and perform better than HD53 mice at 2 (p < 0.05), 6 (p < 0.05), and 8 (p < 0.05) months (ANOVA p < 0.0001; Figure 4A ). As the HD53 mice showed a deficit at the start of the behavior trial, an additional cohort was assessed at 1 month to determine whether baseline rotarod performance is similar between genotypes. At 1 month, all mice perform similarly ( Figure S5 ). The HD53 mice demonstrate a progressive hypokinetic phenotype commencing at 4 months compared to wt during a 30 min open-field trial (p < 0.01; Figure 4B ). In contrast to the HD53 mice, the C6R mice display activity levels indistinguishable from wt at all times tested. Furthermore, the C6R mice perform better than HD53 mice at 6 (p < 0.05), 8 (p < 0.01), and 10 (p < 0.01) months (ANOVA p < 0.0001; Figure 4B ). These results demonstrate that preventing the generation of the caspase-6 cleavage fragment of mhtt is sufficient to prevent the motor dysfunction observed in the YAC model.
Altered Nuclear Translocation of Huntingtin in the Striatum of C6R Mice
Nuclear translocation of htt and formation of inclusions are neuropathological hallmarks of HD (Davies et al., 1997; Gutekunst et al., 1999; Slow et al., 2005) . To investigate whether inhibiting caspase-6 cleavage of mhtt alters nuclear translocation of htt, brain sections from wt, CR, and YAC128 mice were immunostained with EM48, an antibody that recognizes N-terminal htt fragments and is highly specific for inclusions .
EM48 immunoreactivity is not observed in wt striatum at any time point. However, diffuse nuclear htt is observed at 3 months in the striatum of HD53 mice ( Figure 5A ). Nuclear htt increases with age, and by 12 months, the majority of striatal neurons demonstrate extensive EM48 staining ( Figure 5C ). In contrast, nuclear localization of mhtt is delayed in the C6R lines, with just detectable levels in the striatum at 9 months ( Figure 5B ), similar to HD53 striatum at 2 months (Van Raamsdonk et al., 2005a) . Between 9 and 12 months, there is an increase in nuclear htt in the striatum of C6R mice, suggesting that other proteases are activated and generate htt fragments not associated with pathology ( Figures 5B and 5C ).
Low levels of diffuse nuclear htt are observed in HD54 and C3R lines at 18 months ( Figure 5D ). However, in sharp contrast, both CQR lines demonstrate barely detectable levels of EM48 staining at 18 months ( Figure 5E ), consistent with the delay in nuclear htt observed in the C6R lines.
This evidence suggests that nuclear translocation of the caspase-6 fragment of mhtt represents an early neuropathological event in the YAC128 model of HD.
C6R Mice Are Resistant to Excitotoxicity
Overactivation of glutamate receptors has been considered a fundamental underlying mechanism in the early stages of HD (Beal et al., 1986; Albin et al., 1990; Levine et al., 1999; Zeron et al., 2002) . We have demonstrated enhanced susceptibility to glutamate-and NMDAR-mediated excitotoxicity in neonatal medium spiny neurons (MSNs) from multiple YAC lines (Zeron et al., 2002; Graham et al., 2005) . Conversely, MSNs overexpressing htt with a normal CAG size (YAC18) show notably less cell death than wt cultures upon NMDA treatment (Leavitt et al., 2006) , suggesting that htt mediates neuroprotection by blocking excitotoxic cell death.
We next assessed vulnerability to NMDAR-mediated excitotoxicity in primary neonatal MSNs from wt, HD, and CR pups. To be able to pool striata, we first generated homozygous YAC128 (HD55; described in Graham et al., 2005) and CR lines that were matched for equivalent mhtt protein levels ( Figure 6A ). HD55+/À mice express mhtt levels similar to C3R (C3R8)+/+ and CQR (CQR24)+/+ mice and were used as the YAC128 control line for the NMDA experiment. HD55+/+ mice express levels of mhtt similar to C6R (C6R7)+/À mice and were used as the YAC128 control for the NMDA and staurosporine experiment. These primary striatal cultures contain a high level of MSNs as defined by morphology and DARPP-32 staining (>85%) and low levels of glia (<10%) .
Protection from NMDAR-mediated excitotoxic death is observed in MSNs that express CQR mhtt compared with (A-C) EM48 staining in the striatum of HD53 at 3 months shows clear diffuse nuclear htt with no inclusions (A). No EM48 immunoreactivity is observed in wt striatum at any time point. In line HD53, the level of nuclear htt increases with age, and by 12 months, the majority of striatal neurons demonstrate extensive EM48 staining (C). In contrast, nuclear localization of mhtt is delayed in the C6R lines, with just detectable levels in the striatum at 9 months (B). Between 9 and 12 months, there is a significant increase in nuclear htt in the striatum of C6R mice (C). (D) EM48 staining in the striatum of HD54 and C3R mice at 18 months shows clear diffuse nuclear htt. (E) In contrast, nuclear localization of htt is delayed in the CQR lines, with barely detectable levels in the striatum at 18 months. Scale bars = 10 mm; n = 3. (F) C6R mhtt protects against staurosporine-induced apoptotic cell death. YAC128 (HD55) MSNs are more vulnerable to staurosporine (10 mM) mediated death compared to wt MSNs (p < 0.05), while YAC18 MSNs demonstrate neuroprotection and reduced cell death compared to wt (p < 0.001). Notably, MSNs expressing C6R mhtt are less susceptible to staurosporine-mediated cell death than wt (p < 0.001) and display a level of cell death similar to MSNs overexpressing neuroprotective wt htt (YAC18 versus C6R p > 0.05) (ANOVA p < 0.0001). Mean percent apoptotic cells is given ±SD; n = 3. *p < 0.05; **p < 0.01; ***p < 0.001. HD55 (CQR = 2.6 ± 1.2, HD55 = 27.9 ± 6.1, p < 0.001) and wt (wt = 8.6 ± 3.5, p < 0.05, ANOVA p = 0.0007; Figure 6B ). In contrast, MSNs expressing C3R mhtt exhibit increased susceptibility to NMDA compared to wt (C3R = 26.8 ± 1.1, wt = 8.6 ± 3.5, p < 0.01) and a level of vulnerability similar to HD55 neurons (HD55 = 27.9 ± 6.1, p > 0.05, ANOVA p = 0.001; Figure 6C ). Furthermore, C6R neurons are protected against NMDAR-mediated excitotoxicity compared to HD55 (C6R = 2.4 ± 0.73, HD55 = 37.2 ± 7.7, p < 0.001) and wt (wt = 8.6 ± 3.4, p < 0.05, ANOVA p = 0.0003; Figure 6D ). To confirm that protection was due to NMDAR activation, we also treated MSNs with MK801 (20 mM), a NMDAR antagonist, in addition to 500 mM NMDA. Under these conditions, cell death was reduced to baseline conditions in all cultures (Figures 6B-6D ). These data demonstrate that MSNs expressing CQR or C6R mhtt are no longer susceptible to NMDARmediated toxicity as seen in MSNs expressing caspasecleavable (HD55) or C3R mhtt. Primary MSNs expressing CQR or C6R mhtt demonstrate less NMDAR-mediated apoptotic death than wt neurons, suggesting that inhibiting caspase-6 cleavage of mhtt converts a neurotoxic species into one that is neuroprotective.
To determine whether the resistance to excitotoxicity is also observed in vivo, we next examined susceptibility to quinolinic acid (QA) mediated neurotoxicity in 3-monthold wt, HD55, and C6R mice. HD55 animals show enhanced lesion size compared to either C6R (HD55 = 1.9 ± 0.28 mm 3 , C6R = 0.17 ± 0.08 mm 3 , p < 0.0001) or wt mice (wt = 0.91 ± 0.25 mm 3 , p < 0.05, ANOVA p < 0.0001; Figure 6E ). In contrast, C6R mice exhibit reduced lesion volume even compared to wt mice (p < 0.05), showing that C6R htt protects from acute excitotoxicity despite the presence of an expanded polyglutamine tract. We also assessed cell death upon exposure to other apoptotic stimuli including staurosporine. As shown previously , HD55 MSNs are more vulnerable to staurosporine-mediated death (10 mM) compared to wt (HD55 = 42.7 ± 2.4, wt = 36.8 ± 1.3, p < 0.05), while YAC18 MSNs demonstrate neuroprotection and reduced cell death compared to wt MSNs (YAC18 = 17.4 ± 0.9, p < 0.001; Figure 6F ). Notably, MSNs expressing C6R mhtt are less susceptible to staurosporine-mediated cell death than wt (C6R = 20.0 ± 1.2, p < 0.001) and display a level of cell death similar to MSNs that overexpress neuroprotective wt htt (YAC18 versus C6R p > 0.05; Figure 6F ) (ANOVA p < 0.0001).
DISCUSSION
The results presented in this study are consistent with caspase cleavage of mhtt being a crucial event in the pathogenesis of HD. Here we demonstrate that specific proteolytic cleavage at the caspase-6 site in mhtt is essential for the HD-related behavioral phenotype and selective neuropathology observed in the YAC128 model of HD. Nuclear translocation of mhtt fragments coincides with onset of motor dysfunction in the YAC128 model, supporting a role for a specific nuclear htt fragment in initiating neuronal dysfunction. Furthermore, caspase-6 cleavage of mhtt influences susceptibility to excitotoxic stress, highlighting caspase-6-mediated proteolysis of htt and excitotoxicity as primary mechanisms of striatal neuronal loss in HD. This evidence suggests that generation of a specific fragment of mhtt in vivo may represent an initiating event in the pathogenesis of HD.
Numerous in vitro and in vivo studies have demonstrated that mhtt toxicity occurs via formation of N-terminal htt fragments containing expanded CAG repeats (Davies et al., 1997; Hackam et al., 1998; Schilling et al., 1999) . However, not all N-terminal fragments of mhtt demonstrate selective HD-related toxicity. HD cell culture models that selectively express the exon 1 fragment of mhtt have been the most extensively studied, yet no protease described thus far cleaves htt to release a fragment that corresponds to exon 1. Furthermore, nonselective expression of a pure expanded CAG tract also results in in vitro and in vivo toxicity, but this represents general polyglutamine toxicity and does not address pathways specific to HD (Ordway et al., 1997) . Additionally, increasing evidence in vitro and in vivo supports the specific protein context of the mhtt fragments in initiating toxicity (Yu et al., 2003; Slow et al., 2005) . These observations suggest that the selective neurodegeneration in HD may be mediated by a specific N-terminal fragment of mhtt.
Using striatal volume as a primary endpoint, we show that specific caspase fragments of mhtt are crucial for neurodegeneration in vivo. Specifically, inhibiting caspase-6 and not caspase-3 cleavage of mhtt protects against striatal volume and neuronal loss. This result highlights the caspase-6 fragment of mhtt (586 aa) as a toxic fragment. The hypothesis that a specific fragment may underlie disease pathogenesis has been well characterized in Alzheimer's disease (AD). Amyloid-b precursor protein (APP) is also cleaved by proteases, leading to generation of Ab42 fragments, which play an essential role in initiating the neurodegeneration observed in AD (Iijima et al., 2004) . Selective downregulation of the toxic Ab42 fragment, and not Ab40, by therapeutic drugs such as NSAID ameliorates the disease phenotype in mouse models of AD showing differences in toxicity levels of fragments with only a 2 aa difference (Eriksen et al., 2003) .
A significant finding in the C6R mice, in addition to the absence of neurodegeneration, is the lack of a behavioral phenotype, indicating that the caspase-6 fragment of mhtt plays a rate-limiting role in the neuronal dysfunction observed in the YAC128 model. Translocation of htt fragments to the nucleus coincide with onset of motor abnormalities in the YAC128 model, suggesting that neuronal dysfunction may be associated with translocation of this fragment. In contrast, blocking formation and translocation of the caspase-6 mhtt fragment in the C6R mice ameliorates the behavioral phenotype. Translocation of htt to the nucleus is associated with increased toxicity in vitro and neuropathology in vivo (Wheeler et al., 2000; Kim et al., 2001; Wellington et al., 2002) . However, the shortstop mouse exhibits widespread diffuse nuclear htt yet demonstrates no clinical phenotype , supporting the hypothesis that it is a specific nuclear htt fragment that underlies the neuronal degeneration observed in HD.
Nuclear translocation of htt fragments does occur in the C6R mice, but it is delayed compared to HD53 mice. The caspase-6 fragment is not produced in C6R mice; therefore, the htt fragments detected in the nuclei of C6R mice later must result from alternative proteolytic pathways, which may include calpains and other caspases. Calpain activation is detected in the 3-NP model of HD, and this was associated with calpain-dependent cleavage of htt (Bizat et al., 2003) . Furthermore, selective calpain inhibition reduced the size of the striatal lesion and abolished 3-NP-induced DNA fragmentation in striatal cells. Interestingly, in rats, intracerebroventricular infusion of zVAD, a broad-spectrum caspase inhibitor, significantly reduced 3NP-induced striatal degeneration and decreased the 3NP-induced activation of calpain (Bizat et al., 2005) . There may be sequential pathways of htt proteolysis, and further cleavage of caspase-derived htt fragments by calpains may generate fragments capable of passive diffusion into the nucleus (Kim et al., 2001) . However, the results of our study place cleavage of htt at the caspase-6 site as a rate-limiting proteolytic event in the pathogenesis of HD, as blocking htt cleavage at this site is sufficient to provide in vitro and in vivo protection from a variety of toxic insults.
Excitotoxicity has been implicated as fundamental in the earliest stages of HD (Beal et al., 1986; Albin et al., 1990 Albin et al., , 1992 Zeron et al., 2002) . Significantly increased NMDAR-mediated current density and/or enhanced susceptibility to glutamate and NMDA have been observed in numerous HD mouse models (Levine et al., 1999; Zeron et al., 2002; Shehadeh et al., 2005; Graham et al., 2005) . Furthermore, striatal glutamate receptors show disproportionate loss in HD human brain (Albin et al., 1992) , and excitotoxic lesions from glutamate intrastriatal injections in mice and primates closely resemble the neuropathology in HD (Beal et al., 1986) .
In contrast, overexpression of wild-type htt has been shown to be neuroprotective in a number of stressinduced model systems, including NMDAR-mediated excitotoxicity, QA-induced neurotoxicity, and ischemia (Zhang et al., 2003; Leavitt et al., 2006) . While the underlying mechanism by which htt mediates neuroprotection is currently unclear, htt has been shown to interact with caspase-2, suggesting a possible role for htt as a caspase inhibitor . It has been demonstrated that the neuroprotective role of htt lies upstream of caspase-3 and may take place at the level of initiator caspases (Rigamonti et al., 2001) .
In this study, we demonstrate that caspase-6-but not caspase-3-resistant mhtt protects neurons from excitotoxic stress, supporting the hypothesis that not all mhtt fragments contribute to excitotoxic death. It has been previously demonstrated in vitro using transfected HEK293 cells that enhanced NMDAR-mediated cell death is not observed with a 548 aa N-terminal fragment of mhtt similar to the caspase-3 fragment of htt (Zeron et al., 2001) . In addition, truncated mouse models including R6, N171, and shortstop demonstrate resistance to QA-induced excitotoxicity (Hansson et al., 1999; Jarabek et al., 2004; Slow et al., 2005) . Thus, no excitotoxicity is observed in vivo with expression of 97, 117, or 171 aa mhtt fragments. These findings suggest that caspase-6 cleavage of mhtt selectively mediates susceptibility to excitotoxic stress via a specific mhtt fragment.
In this study, we demonstrate that a specific mhtt fragment contributes to the selective striatal neurodegeneration observed in the YAC128 model. Furthermore, the protection observed from expression of C6R mhtt is independent of the particular apoptosis-inducing signal, as protection from staurosporine is also observed. While all of the evidence supports the 586 aa site in htt as a caspase-6 site in vitro, it cannot be definitively excluded that in vivo other proteases may cleave htt at this site. Activation of caspase-6 may also contribute to pathogenesis via cleavage and degradation of key survival proteins such as CBP, Akt, and NF-kb. In addition, it cannot be ruled out that altering the 586 aa site in mhtt has affected conformational changes, stability, and/or clearance of full-length mhtt. Precisely how the caspase-6 mhtt fragment leads to the selective neuronal degeneration and behavioral abnormalities seen in this YAC model is unclear. This could be mediated either directly by the toxicity of this particular fragment itself or via activation of other pathways crucial to the pathogenesis of HD.
Our in vivo and in vitro characterization of caspaseresistant mhtt provides substantial support for the hypothesis that cleavage at the caspase-6 site in mhtt represents a crucial rate-limiting event in the pathogenesis of HD. Furthermore, we demonstrate a strong correlation between excitotoxicity and the disease phenotype, suggesting links between proteolysis of htt and excitotoxicity. Our study highlights the importance of preventing cleavage of htt at this site and also reinforces the importance of modulating excitotoxicity as a potential therapeutic approach for HD.
EXPERIMENTAL PROCEDURES
Generation of YAC Transgenic Mice
Verified CR YACs were purified by pulsed-field electrophoresis and microinjected into FVB/N oocytes. PCR of the CAG repeat was as described .
Real-Time Quantitative RT-PCR Total RNA was extracted from mouse cortex with RNeasy Protect Mini Kit (QIAGEN). First-strand cDNA was prepared using SuperScript First-Strand Synthesis System (Invitrogen). Human-specific HD and mouse-specific b-actin primers and RT-PCR were as described . Amplification of mouse b-actin was performed to standardize the amount of sample RNA added to the reaction. HD gene-expression levels were measured using the RQ Study Add On software (ABI).
Protein Analysis and Western Blotting Protein was prepared as described . One hundred micrograms was run on 7.5% or 10% low bis-polyacrylamide gels; transferred to PVDF membranes; and then probed with BKP1 (Hodgson et al., 1999) , 1C2 (MAB1574, Chemicon), or Actin (Sigma). Densitometric values from scanned Western blots were obtained using Quantity One (Bio-Rad).
Ex Vivo Confirmation of Caspase-Resistant htt Whole mouse brain protein lysates were prepared as described without zVAD added in the lysis buffer. Ex vivo cleavage of htt was as per Wellington et al. (1998) . Protein was transferred onto PVDF membranes (Millipore) and then probed with BKP1.
Rescue of Embryonic Lethality of htt-Deficient Mice FVB/N mice expressing the HD or CR YAC were crossed to mice heterozygous for the murine HD gene. Tail DNA was screened for the YAC and genotyped for the null allele as described (Hodgson et al., 1996) . Genotypes were analyzed by chi-square analysis (GraphPad Prism 4.0).
Quantitative Neuropathological Analysis
All quantitative analysis was done blind to genotype. Mice were weighed, terminally anesthetized by intraperitoneal injection of 2.5% avertin, and perfused with 3% paraformaldehyde/0.15% glutaraldehyde in PBS. The brains were immersed in 3% paraformaldehyde for 24 hr at 4ºC then removed and stored in PBS. Mouse brains were cut using a vibratome, and coronal sections (25 mm) spaced 200 mm apart throughout the striatum were stained with NeuN (Chemicon) as described previously (Slow et al., 2003) . Striatal volume and neuronal counts were assessed as described previously (Slow et al., 2003) .
Behavior
Wild-type, HD53, and C6R7 mice were group housed in microisolator cages with a normal light-dark cycle. Mice were randomly coded and the tester was blind to the genotypes. Rotarod analysis was as described (Van Raamsdonk et al., 2005c) . Open-field analysis was conducted in the dark in an automated open-field activity apparatus (San Diego Instruments). Measurements were calculated by accompanying software, Photobeam Analysis System (San Diego Instruments).
Assessment of htt552 and Nuclear Huntingtin Perfused brain sections were immunoassayed with htt552 or EM48 as described Gutekunst et al., 1999) . Biotinylated secondary antibodies (Vector) were used at 1:200 prior to signal amplification with an ABC Elite kit (Vector) and detection with DAB (Pierce). Photographs were taken on a light microscope using an 1003 objective.
NMDAR-Mediated Excitotoxicity
Pooled cultures (6-10 pups) of primary MSNs were prepared from newborn pups (P0-P1) as described . Cultures were maintained in vitro for 9-10 days prior to treatment with balanced salt solution, 500 mM NMDA (Sigma), or 500 mM NMDA + 20 mM MK801 and assessed for apoptotic cell death as described . Exposure of MSNs to staurosporine was for 24 hr using 100 nM and 10 mM doses. For each experiment (n = 3), all treatments were done blind and in triplicate, and a minimum of 1000 cells were counted.
Quinolinic-Acid Injections QA (Sigma) was dissolved into 0.1 M PBS. Mice were anesthetized with isofluorane and received bilateral intrastriatal injections of 4 nM quinolinic acid. Seven days postinjection, mice were terminally anesthetized, perfused, and analyzed as described (Zeron et al., 2002) .
Statistical Analyses
All statistical analyses were done using one-way or repeated-measures ANOVA (in cases of significant effect of genotype, post hoc comparisons between genotypes were performed using Tukey's test) or the unpaired two-tailed Student's t test. p values, SEM, means, SD, and chi-square analysis were calculated using Graphpad Prism version 4.0.
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